Amino-truncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

Clinical Chemistry

Volumn 51, Issue 9, 2005, Pages 1650-1660

  Vanderstichele, Hugo ^a,e   De Meyer, Geert ^a   Andreasen, Niels ^b   Kostanjevecki, Vesna ^a   Wallin, Anders ^c   Olsson, Annika ^d   Blennow, Kaj ^d   Vanmechelen, Eugeen ^a  

^a INNOGENETICS   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Box 4 ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AREA UNDER THE CURVE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR WEIGHT; PREDICTION; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; ROC CURVE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 24144443470     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.051201     Document Type: Article

References (38)

1. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988;38:1688-93.
2. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003;2:15-21.
3. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16.
4. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
5. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90.
6. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun Mass Spectrom 2003;17: 1291-6.
7. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, et al. Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 2004;55:524-30.
8. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003;85:1581-91.
9. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, et al. Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 2001;276:42645-57.
10. Oliver KG, Kettman JR, Fulton RJ. Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clin Chem 1998;44: 2057-60.
11. 181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-45.
12. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
13. (1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
14. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-45.
15. Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J-J, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61: 1828-34.
16. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 1999;10:1699-705.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
19. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47: 1113-24.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55: 181-4.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
22. Temple R. Are surrogate markers adequate to address cardiovascular disease drugs? JAMA 1998;282:790-5.
23. Wahlund L-O, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003;339:99-102.
24. Clarke EE, Shearman MS. Quantitation of amyloid-" peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. J Neurosci Methods 2000;102:61-8.
25. Ida N, Hartmann T, Pantel J, Schröder J, Zerfass R, Förstl H, et al. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J Biol Chem 1996;271:22908-14.
26. Gouras GK, Xu H, Jovanovic JN, Buxbaum JD, Wang R, Greengard P, et al. Generation and regulation of β-amyloid peptide variants by neurons. J Neurochem 1998;71:1920-5.
27. Larner AJ. Hypothesis: amyloid β-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. Neurobiol Aging 1999;20:65-9.
28. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, et al. APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 2002;41:922-8.
29. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 2000;276:422-7.
30. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid β-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 1997;409: 411-6.
31. Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997;48:41-5.
32. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003; 15:169-76.
33. Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, et al. Appearance of sodium dodecyl sulfate-stable amyloid β-protein (Aβ) dimer in the cortex during aging. Am J Pathol 1999;154:271-9.
34. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998;4:832-4.
35. Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, et al. Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 1997;272: 7977-82.
36. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999;274:25945-52.
37. Larner AJ. Physiological and pathological interrelationships of amyloid β peptide and the amyloid precursor protein. Bioassays 1995;17:819-24.
38. De Meyer G, Shapiro F. Biomarker development: the road to clinical utility. Current Drug Discovery 2003;May:23-7.